Letter to the Editor
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

https://doi.org/10.1016/j.jaci.2020.05.002Get rights and content

Cited by (0)

Disclosure of potential conflict of interest: R. Caorsi receives speaker’s fees and has consultancies for Novartis and SOBI. A. Ravelli receives speaker’s fees and has consultancies for Novartis and SOBI. M. Gattorno receives speaker’s fees and has consultancies for Novartis and SOBI. The rest of the authors declare that they have no relevant conflicts of interest.

These authors contributed equally to this work.

View Abstract